These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 32505900)
1. Comprehensive analysis of CTLA-4 in the tumor immune microenvironment of 33 cancer types. Zhang C; Chen J; Song Q; Sun X; Xue M; Yang Z; Shang J Int Immunopharmacol; 2020 Aug; 85():106633. PubMed ID: 32505900 [TBL] [Abstract][Full Text] [Related]
2. Comprehensive Transcriptomic Analysis Reveals the Role of the Immune Checkpoint HLA-G Molecule in Cancers. Xu HH; Gan J; Xu DP; Li L; Yan WH Front Immunol; 2021; 12():614773. PubMed ID: 34276642 [TBL] [Abstract][Full Text] [Related]
3. Tumor microenvironment-related gene selenium-binding protein 1 (SELENBP1) is associated with immunotherapy efficacy and survival in colorectal cancer. Zhu C; Wang S; Du Y; Dai Y; Huai Q; Li X; Du Y; Dai H; Yuan W; Yin S; Wang H BMC Gastroenterol; 2022 Oct; 22(1):437. PubMed ID: 36253721 [TBL] [Abstract][Full Text] [Related]
4. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells. Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085 [TBL] [Abstract][Full Text] [Related]
5. Genetic variations in the CTLA-4 immune checkpoint pathway are associated with colon cancer risk, prognosis, and immune infiltration via regulation of IQCB1 expression. Ben S; Zhu Q; Chen S; Li S; Du M; Xin J; Chu H; Zhang Z; Wang M Arch Toxicol; 2021 Jun; 95(6):2053-2063. PubMed ID: 33847778 [TBL] [Abstract][Full Text] [Related]
6. A matrix metalloproteinase inhibitor enhances anti-cytotoxic T lymphocyte antigen-4 antibody immunotherapy in breast cancer by reprogramming the tumor microenvironment. Li M; Xing S; Zhang H; Shang S; Li X; Ren B; Li G; Chang X; Li Y; Li W Oncol Rep; 2016 Mar; 35(3):1329-39. PubMed ID: 26752000 [TBL] [Abstract][Full Text] [Related]
7. Clinical Implications of Aberrant PD-1 and CTLA4 Expression for Cancer Immunity and Prognosis: A Pan-Cancer Study. Liu JN; Kong XS; Huang T; Wang R; Li W; Chen QF Front Immunol; 2020; 11():2048. PubMed ID: 33072070 [TBL] [Abstract][Full Text] [Related]
8. Bioinformatics and survival analysis of glia maturation factor-γ in pan-cancers. Lan A; Ren C; Wang X; Tong G; Yang G BMC Cancer; 2021 Apr; 21(1):423. PubMed ID: 33863293 [TBL] [Abstract][Full Text] [Related]
9. MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers. Peng L; Chen Z; Chen Y; Wang X; Tang N Cancer Med; 2019 Dec; 8(17):7161-7173. PubMed ID: 31568700 [TBL] [Abstract][Full Text] [Related]
10. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Havel JJ; Chowell D; Chan TA Nat Rev Cancer; 2019 Mar; 19(3):133-150. PubMed ID: 30755690 [TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes. Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813 [TBL] [Abstract][Full Text] [Related]
13. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma. Zuo S; Wei M; Wang S; Dong J; Wei J Front Immunol; 2020; 11():1218. PubMed ID: 32714316 [No Abstract] [Full Text] [Related]
14. A pan-cancer study of PD-1 and CTLA-4 as therapeutic targets. Cai Z; Ang X; Xu Z; Li S; Zhang J; Pei C; Zhou F Transl Cancer Res; 2021 Sep; 10(9):3993-4001. PubMed ID: 35116697 [TBL] [Abstract][Full Text] [Related]
15. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366 [TBL] [Abstract][Full Text] [Related]
16. Immune and Stroma Related Genes in Breast Cancer: A Comprehensive Analysis of Tumor Microenvironment Based on the Cancer Genome Atlas (TCGA) Database. Xu M; Li Y; Li W; Zhao Q; Zhang Q; Le K; Huang Z; Yi P Front Med (Lausanne); 2020; 7():64. PubMed ID: 32195260 [No Abstract] [Full Text] [Related]
17. Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis. Yu H; Yang J; Jiao S; Li Y; Zhang W; Wang J Cancer Immunol Immunother; 2015 Jul; 64(7):853-60. PubMed ID: 25893809 [TBL] [Abstract][Full Text] [Related]
18. The immune checkpoint VISTA is associated with prognosis in patients with malignant uveal melanoma. Issam Salah NEI; Marnissi F; Lakhdar A; Karkouri M; ElBelhadji M; Badou A Front Immunol; 2023; 14():1225140. PubMed ID: 37662962 [TBL] [Abstract][Full Text] [Related]
19. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720 [TBL] [Abstract][Full Text] [Related]
20. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Lei X; Lei Y; Li JK; Du WX; Li RG; Yang J; Li J; Li F; Tan HB Cancer Lett; 2020 Feb; 470():126-133. PubMed ID: 31730903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]